WVE vs. NUVB, SAGE, COGT, CVAC, NRIX, PAHC, ANAB, AUPH, PRTC, and GHRS
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include Nuvation Bio (NUVB), Sage Therapeutics (SAGE), Cogent Biosciences (COGT), CureVac (CVAC), Nurix Therapeutics (NRIX), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Aurinia Pharmaceuticals (AUPH), PureTech Health (PRTC), and GH Research (GHRS). These companies are all part of the "pharmaceutical preparations" industry.
Nuvation Bio (NYSE:NUVB) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
Nuvation Bio has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -0.99, suggesting that its stock price is 199% less volatile than the S&P 500.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by insiders. Comparatively, 31.1% of Wave Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Wave Life Sciences has higher revenue and earnings than Nuvation Bio. Wave Life Sciences is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences received 315 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 72.09% of users gave Nuvation Bio an outperform vote while only 67.18% of users gave Wave Life Sciences an outperform vote.
Nuvation Bio currently has a consensus target price of $6.60, suggesting a potential upside of 98.80%. Wave Life Sciences has a consensus target price of $10.25, suggesting a potential upside of 63.74%. Given Wave Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Wave Life Sciences.
In the previous week, Nuvation Bio had 2 more articles in the media than Wave Life Sciences. MarketBeat recorded 13 mentions for Nuvation Bio and 11 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 0.46 beat Nuvation Bio's score of 0.26 indicating that Nuvation Bio is being referred to more favorably in the media.
Nuvation Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -54.61%. Nuvation Bio's return on equity of 0.00% beat Wave Life Sciences' return on equity.
Summary
Nuvation Bio beats Wave Life Sciences on 11 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
